[Diagnostic and Therapeutic Approaches for Mitochondrial Diseases]. / Diagnostik und Therapie Mitochondrialer Erkrankungen.

Mitochondrial diseases (MD) represent a heterogenous group of disorders and syndromes caused either by mutations of the mitochondrial DNA (mtDNA) or the nuclear DNA (nDNA). They belong to the most frequent neurogenetic diseases. The spectrum of clinical manifestations is very broad ranging from mild subclinical presentations to rapidly progressive debilitating conditions with reduced life expectancy. Mitochondrial dysfunction can affect any organ of the body; the clinical presentation is often most severe in tissues with high energy demands. The most common MD are Leber's Hereditary Optic Neuropathy (LHON), Chronic Progressive External Ophthalmoplegia (CPEO), Kearns-Sayre Syndrome (KSS), Mitochondrial Myopathy (MM) and Mitochondrial Encephalomyopathy, Lactic Acidosis and Strokelike episodes (MELAS). In the last couple of years, genetics have become more and more important for the diagnosis of MD. The majority of syndromes presents with a characteristic combination of clinical and laboratory findings which should guide the selection of tissues (blood cells, fibroblasts, urothelial cells or muscle) and methods for targeted genetic testing. Therapeutic approaches to MD include pharmacological stimulation of mitochondrial metabolism, supplementation, symptomatic treatment, assistive devices and physiotherapy. Moreover, strict anti-epileptic therapy and treatment or prevention of stroke-like episodes are very important to prevent complications. In contrast, some medication should be avoided for its direct or indirect depressing effect on mitochondrial function. This article provides an introduction to mitochondrial diseases, an overview of the most common syndromes and an update on established and new therapeutic approaches.